Safety of Intranasally Administered Archaeal Lipid Mucosal Vaccine Adjuvant and Delivery (AMVAD) Vaccine in Mice

• Published in: International journal of toxicology Vol. 27; no. 4; pp. 329 - 339
• Main Authors: Patel, Girishchandra B., Ponce, Amalia, Zhou, Hongyan, Chen, Wangxue
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01-07-2008
• Subjects: Adjuvants, Immunologic - administration & dosage; Administration, Intranasal; Animals; Archaea - chemistry; Enzyme-Linked Immunosorbent Assay; Lipids - administration & dosage; Methanobrevibacter smithii; Mice; Mucous Membrane - metabolism; Organ Size; Vaccines - administration & dosage; Vaccine; Safety; Intranasal; Archaeal Lipid
• ISSN: 1091-5818; 1092-874X
• DOI: 10.1080/10915810802352703

The safety profile of a recently described novel archaeal lipid mucosal vaccine adjuvant and delivery (AMVAD) system capable of eliciting robust antigen-specific mucosal and systemic immune responses was evaluated in female Balb/c mice (10/group) using ovalbumin (OVA) antigen. Mice were intranasally immunized (0, 7, and 21 days) with a vaccine comprising 1 μg OVA (0.05 mg/kg body weight) formulated in 0.04 mg total polar lipids extract (2.17 mg/kg body weight) of Methanobrevibacter smithii constituting the AMVAD system. Control groups were similarly immunized with 10-fold higher AMVAD vaccine dose (0.54 mg OVA and 21.7 mg lipid per kg), saline, 10 μg OVA in saline, or 0.04 or 0.4 mg lipid constituting empty AMVAD (no OVA) in saline, or were naïve mice. Clinical signs, rectal temperature, and body weight were monitored once daily or as appropriate. Half the mice in each group were euthanized at 2 days after the first immunization. Blood was collected for clinical chemistry analyses. Major organs (heart, lungs, kidneys, liver, spleen, thymus, and brain) were examined macroscopically and histologically. The remaining mice were euthanized at 29 days and blood and organs collected for analyses as done at 2 days. Feces collected at 27 days, and sera, bile, and nasal lavage at 29 days, were assayed for antibody responses. Based on clinical symptoms, temperature, body weight changes, serum clinical chemistry, and tissue histopathology, there were no overt toxicities associated with OVA/AMVAD or empty AMVAD vaccines. There were no antibodies elicited against the lipids comprising the AMVAD system. These results demonstrate that at 10-fold excess dose of that required for vaccine efficacy, intranasally administered AMVAD vaccine appears to be relatively safe.